Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | 5/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 9 Years | 12 Years | ||
Fund Size | 1232 Cr | 8352 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.63% | 0.89% | ||
Exit Load | 0.25% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.64%) Apollo Hospitals Enterprise Ltd (6.22%) Cipla Ltd (5.83%) Aurobindo Pharma Ltd (5.73%) Divi's Laboratories Ltd (5.63%) | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (97.4%) Basic Materials (2.6%) | Health (100%) | ||
Equity % | 90.84% | 98.58% | ||
Debt % | - | - | ||
P/E | 35.88 | 36.85 | ||
P/B | 5.3 | 5.96 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.14% | 0.53% | ||
3-Month Return | 4.22% | 4.6% | ||
6-Month Return | -4.91% | -2.54% | ||
1-Year Return | 13.48% | 13.27% | ||
3-Year Return | 26.9% | 26.67% | ||
5-Year Return | 22.9% | 22.65% |
Sharpe | 1.04 | 1.13 | ||
Alpha | 4.08 | 1.66 | ||
Beta | 0.95 | 0.9 | ||
Standard Deviation | 16.18 | 14.97 | ||
Information Ratio | 1.33 | 0.02 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Meeta Shetty | Sailesh Raj Bhan,Kinjal Desai |